Ad-Pharmachem Profile
Key Indicators
- Authorised Capital ₹ 3.00 M
as on 27-06-2024
- Paid Up Capital ₹ 2.74 M
as on 27-06-2024
- Company Age 26 Year, 4 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 9.33 Cr
as on 27-06-2024
- Satisfied Charges ₹ 3.52 Cr
as on 27-06-2024
- Revenue 71.75%
(FY 2023)
- Profit -77.14%
(FY 2023)
- Ebitda -7.08%
(FY 2023)
- Net Worth 7.41%
(FY 2023)
- Total Assets 19.10%
(FY 2023)
About Ad-Pharmachem
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 3.00 M and a paid-up capital of Rs 2.74 M.
The company currently has active open charges totaling ₹9.33 Cr. The company has closed loans amounting to ₹3.52 Cr, as per Ministry of Corporate Affairs (MCA) records.
Anup Dinkar, Pushpa Dinkar, and Dinkar Arbale serve as directors at the Company.
- CIN/LLPIN
U24230MH1998PTC116404
- Company No.
116404
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
02 Sep 1998
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Aurangabad, Maharashtra, India
- Telephone
- Email Address
- Website
- Social Media-
What products or services does Ad-Pharmachem Private Limited offer?
Ad-Pharmachem Private Limited offers a wide range of products and services, including Organic and Inorganic Solvents, Organic Chemicals, Chemical Reagents & Catalysts, Catalysts, Industrial Chemicals & Supplies, Biocides, Bromine Compound, Industrial Acid.
Who are the key members and board of directors at Ad-Pharmachem?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Anup Dinkar  | Director | 15-Apr-2008 | Current |
| Pushpa Dinkar | Director | 02-Sep-1998 | Current |
| Dinkar Arbale | Director | 02-Sep-1998 | Current |
Financial Performance of Ad-Pharmachem.
Ad-Pharmachem Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 71.75% increase. The company also saw a substantial fall in profitability, with a 77.14% decrease in profit. The company's net worth moved up by a moderate rise of 7.41%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Ad-Pharmachem?
In 2023, Ad-Pharmachem had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Sidbi Creation Date: 04 Jan 2023 | ₹1.03 Cr | Open |
Others Creation Date: 26 Nov 2021 | ₹8.30 Cr | Open |
State Bank Of India Creation Date: 20 Jun 2007 | ₹2.97 Cr | Satisfied |
How Many Employees Work at Ad-Pharmachem?
Unlock and access historical data on people associated with Ad-Pharmachem, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Ad-Pharmachem, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Ad-Pharmachem's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
